No CrossRef data available.
Article contents
Pharmacy Benefit Management: The Cost of Drug Price Rebates
Published online by Cambridge University Press: 04 March 2024
Abstract
Pharmacy Benefit Managers (PBM) induce drug manufacturers to offer rebates to insurers and employers by denying coverage through formulary exclusions, impeding physician prescription through prior authorization, and reducing patient drug use through cost sharing. As they tighten these access obstacles, PBMs reduce the net prices received by the manufacturers.
- Type
- Commentary
- Information
- Copyright
- © 2023 The Author(s)
References
Resources
A.J. Fein, The 2022 Economic Report on US Pharmacies and Pharmacy Benefit Managers (March 15, 2022), Drug Channels, available at <https://www.drugchannels.net/2022/03/now-available-2022-economic-report-on.html> (last visited November 26, 2023).+(last+visited+November+26,+2023).>Google Scholar
2022 Biosimilars Trend Report (2022), Amgen Biosimilars, available at <https://www.amgenbiosimilars.com/commitment/2022-Biosimilar-Trends-Report> (last visited November 26, 2023).+(last+visited+November+26,+2023).>Google Scholar
Five Takeaways from the Big Three PBMs’ 2022 Formulary Exclusions (rerun), Drug Channels, available at <https://www.drugchannels.net/2022/04/five-takeaways-from-big-three-pbms-2022.html> (last visited November 26, 2023).+(last+visited+November+26,+2023).>Google Scholar
S.D. Pearson et al., Cornerstones of Fair Drug Coverage: Appropriate Cost Sharing and Utilization Management Policies for Pharmaceuticals (September 28, 2020), Institute for Clinical and Economic Review, available at <https://icer.org/wp-content/uploads/2020/11/Cornerstones-of-Fair-Drug-Coverage-_-September-28-2020.pdf> (last visited November 26, 2023).+(last+visited+November+26,+2023).>Google Scholar
2022 Employer Health Benefits Survey (October 27, 2022), KFF, available at <https://www.kff.org/health-costs/report/2022-employer-health-benefits-survey/> (last visited November 26, 2023).+(last+visited+November+26,+2023).>Google Scholar
Park, Y. et al., “The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review,” Journal of Managed Care and Specialty Pharmacy, 23, no. 8 (2017): 893–901, available at <https://www.jmcp.org/doi/10.18553/jmcp.2017.23.8.893> (last visited November 26, 2023).Google ScholarPubMed
Howell, S., Yin, P., and Robinson, J.C., “Quantifying the Burden of Drug Utilization Management on Payers, Manufacturers, Physicians, and Patients,” Health Affairs 40, no. 8 (2021): 1206–1214, available at <https://pubmed.ncbi.nlm.nih.gov/34339243/> (last visited November 26, 2023)Google ScholarPubMed
Robinson, J.C., Howell, S., and Pearson, S.D., “Value-Based Pricing and Patient Access for Specialty Drugs,” JAMA 310, no. 21 (2018): 2169–70, available at <https://pubmed.ncbi.nlm.nih.gov/29801023/> (last visited November 26, 2023).CrossRefGoogle Scholar